Mid-Day Trend Analysis Reports For: (NASDAQ: AEZS), (NASDAQ: CALL)
AEternaZentaris Inc. (NASDAQ: AEZS), a late-stage drug development company specializing in oncology and endocrine therapy, is soaring in mid-day trading today after the company announced that it has been granted a Special Protocol Assessment (SPA) by the U.S. FDA for Phase 3 registration trial in endometrial cancer with AEZS-108. Juergen Engel, Ph. D., President and CEO of AEZS, said that he is pleased with the agreement with the FDA which provides the company with a clearly defined development and regulatory...
View full press release